-
Most Popular
Search Results
240 results for bmti
Bristol-Myers Squibb Is a Dirt-Cheap Buy Before Earnings
Thanks to its Celgene acquisition, Bristol-Myers Squibb looks attractive ahead of earnings. Here’s why you should buy BMY stock.
Buy Bristol-Myers Squibb Co (BMY) Stock With No Fear
BMY is rallying on solid fundamentals to reclaim a long-term pivot levels as support for even higher prices. Go long on strong support.
BMY Pummeled After Earnings, But Bristol-Myers Squibb Stock Still a Buy
Bristol-Myers Squibb stock has a lot going for it, like the company’s newfound focus on hepatitis C, oncology and immunotherapy. But BMY still might need…
BMY Stock Looks Really Appetizing as the Celgene Merger Approaches
Is Bristol-Myers Squibb stock a buy now? If you’re patient enough to wait out the merger jitters, there’s a lot to like.
Risk-Takers Have a Reasonable Shot with BMY Stock
Political pressures regarding drug pricing and Bristol-Myers’ disappointing clinical trails have contributed to a disappointing performance for BMY stock. Still, much of this bearishness could…
Weekly Upgrades and Downgrades
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to…
Bristol-Myers Squibb Stock Has Upside — But Mind the Risks
Bristol-Myers Squibb stock touched a multi-year low last month. But the BMY stock price is cheap enough now to take on real risks.
Is It Time to Sell Celgene Stock After the Bristol-Myers Squibb Offer?
Celgene shareholders who bought CELG stock at lows last year started 2019 on a bright note; Bristol-Myers is buying it for $74 billion.
Why Is Bristol-Myers Near 52-Week Lows?
Investors are punishing Bristol-Myers on the markets more than they should. BMY stock’s acquisition of Celgene isn’t the only reason.
Why Bristol-Myers Squibb Co (BMY) Shares Are Sinking Today
Bristol-Myers Squibb (BMY) stock took a hit today after AstraZeneca (AZN) reported a failed drug test, despite its positive earnings report.
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
Bristol-Myers Squibb stock is falling on Monday as investors in BMY shares react to two updates weighing on the company’s stock.
Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?
Is Celgene Stock Still Worth Holding Onto in the Long Run?
Celgene and Bristol-Myers got the green light from shareholders to move forward on the deal. More upside awaits for CELG stock.
The Recent Selloff Is No Reason to Buy Bristol-Myers Squibb Co Stock
Bristol-Myers stock fell about 4% after reporting earnings. Is it because of its results, or a day where the broader markets fell about the same…
Celgene Stock Surges on Bristol-Myers Mega Deal
Bristol-Myers is taking on the job of bringing Celgene’s big pipeline of anti-cancer drugs to the market, and extracting the most value possible from them.
4 Health Care Equipment & Supplies Stocks to Sell Now
This week, the ratings of 4 Health Care Equipment & Supplies stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or…
BTI Stock Alert: The $31.5 Billion Reason British American Tobacco Is Down Today
British American Tobacco is a cheap stock, with BTI stock yielding nearly 10%. Americans are quitting cigarettes but other people have not.
6 – 10 of 240 results
